Jazz Pharma Reports Q1 Adj. EPS Of $1.99 - Quick Facts

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) reported first-quarter net income attributable to company of $70.7 million, or $1.12 per share, compared to a net loss of $92.7 million, or $1.58 per share, prior year. The company noted that the GAAP net loss attributable to Jazz Pharmaceuticals plc for the first quarter of prior year included acquired in-process research and development expense of $127.0 million.

Adjusted net income attributable to Jazz Pharmaceuticals plc for the first quarter of 2015 was $125.1 million, or $1.99 per share.

On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $2.14 for the quarter. Analysts' estimates typically exclude special items.

Total revenues were $309.3 million, an increase of 25% over total revenues of $246.9 million for the first quarter of 2014. The company said the increase in total revenues was driven primarily by higher net product sales of Xyrem (sodium oxybate) oral solution, Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi) and Defitelio (defibrotide). Analysts expected revenue of $308.92 million for the quarter.

Jazz Pharmaceuticals reaffirmed its full year 2015 financial guidance, and expects: Revenues of $1.31-$1.37 billion; GAAP EPS of $5.17-$5.70; and Non-GAAP EPS of $9.45-$9.75. Analysts expect the company to report fiscal year earnings per share of $9.77 on revenue of $1.36 billion.